BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 12684413)

  • 1. PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma.
    Davidson B; Goldberg I; Gotlieb WH; Kopolovic J; Ben-Baruch G; Reich R
    Clin Cancer Res; 2003 Apr; 9(4):1412-9. PubMed ID: 12684413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma.
    Davidson B; Reich R; Goldberg I; Gotlieb WH; Kopolovic J; Berner A; Ben-Baruch G; Bryne M; Nesland JM
    Clin Cancer Res; 2001 Mar; 7(3):551-7. PubMed ID: 11297247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma.
    Goldberg I; Davidson B; Reich R; Gotlieb WH; Ben-Baruch G; Bryne M; Berner A; Nesland JM; Kopolovic J
    Clin Cancer Res; 2001 Dec; 7(12):4073-9. PubMed ID: 11751504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases-A clinicopathologic study.
    Davidson B; Gotlieb WH; Ben-Baruch G; Kopolovic J; Goldberg I; Nesland JM; Berner A; Bjåmer A; Bryne M
    Gynecol Oncol; 2000 Apr; 77(1):35-43. PubMed ID: 10739688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenic molecule expression is downregulated in effusions from breast cancer patients.
    Konstantinovsky S; Nielsen S; Vyberg M; Kvalheim G; Nesland JM; Reich R; Davidson B
    Breast Cancer Res Treat; 2005 Nov; 94(1):71-80. PubMed ID: 16142438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. E-Cadherin complex protein expression and survival in ovarian carcinoma.
    Davidson B; Gotlieb WH; Ben-Baruch G; Nesland JM; Bryne M; Goldberg I; Kopolovic J; Berner A
    Gynecol Oncol; 2000 Dec; 79(3):362-71. PubMed ID: 11104606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caveolin-1 expression in advanced-stage ovarian carcinoma--a clinicopathologic study.
    Davidson B; Nesland JM; Goldberg I; Kopolovic J; Gotlieb WH; Bryne M; Ben-Baruch G; Berner A; Reich R
    Gynecol Oncol; 2001 May; 81(2):166-71. PubMed ID: 11330944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression.
    Davidson B; Konstantinovsky S; Nielsen S; Dong HP; Berner A; Vyberg M; Reich R
    Clin Cancer Res; 2004 Nov; 10(21):7335-46. PubMed ID: 15534110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
    Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
    Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
    Davidson B; Lazarovici P; Ezersky A; Nesland JM; Berner A; Risberg B; Tropé CG; Kristensen GB; Goscinski M; van de Putte G; Reich R
    Clin Cancer Res; 2001 Nov; 7(11):3457-64. PubMed ID: 11705863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival.
    Davidson B; Hadar R; Stavnes HT; Trope' CG; Reich R
    Hum Pathol; 2009 May; 40(5):705-13. PubMed ID: 19157507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
    Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
    Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma.
    Davidson B; Reich R; Lazarovici P; Nesland JM; Skrede M; Risberg B; Tropé CG; Flørenes VA
    Clin Cancer Res; 2003 Jun; 9(6):2248-59. PubMed ID: 12796393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: a possible activation pathway?
    Davidson B; Goldberg I; Gotlieb WH; Kopolovic J; Risberg B; Ben-Baruch G; Reich R
    Cancer Metastasis Rev; 2003 Mar; 22(1):103-15. PubMed ID: 12716042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma.
    Davidson B; Alejandro E; Flørenes VA; Goderstad JM; Risberg B; Kristensen GB; Trope CG; Kohn EC
    Cancer; 2004 May; 100(10):2139-47. PubMed ID: 15139056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stromelysin 3, Ets-1, and vascular endothelial growth factor expression in oral precancerous and cancerous lesions: correlation with microvessel density, progression, and prognosis.
    Arora S; Kaur J; Sharma C; Mathur M; Bahadur S; Shukla NK; Deo SV; Ralhan R
    Clin Cancer Res; 2005 Mar; 11(6):2272-84. PubMed ID: 15788677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
    Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
    Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
    Konecny G; Untch M; Pihan A; Kimmig R; Gropp M; Stieber P; Hepp H; Slamon D; Pegram M
    Clin Cancer Res; 2001 Jun; 7(6):1743-9. PubMed ID: 11410515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.